C4 Therapeutics, Inc.
Moat Score — C4 Therapeutics, Inc.
Total Moat Score
4 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | C4's proprietary TORPEDO targeted protein degradation platform is protected by a real, differentiated patent estate in small-molecule degrader chemistry, and has attracted major pharma validation through collaborations with Roche and Merck KGaA (up to $740 million in potential milestones). |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a clinical-stage biopharmaceutical company with no approved products and net losses of roughly $105 million in both 2025 and 2024, C4 has no cost advantage; it is entirely dependent on partner payments and capital markets to fund R&D. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | With cemsidomide still in Phase 2 and CFT8919 in Phase 1, C4 has no commercial products and therefore no current pricing power; any future pricing power depends entirely on clinical and regulatory success. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Drug discovery and development exhibits no network effect. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 0 / 5 | With no marketed products, there are no customers or prescribers to exhibit switching costs; partnership agreements with Roche, Merck KGaA, and Betta Pharma are collaboration structures rather than customer lock-in. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | Targeted protein degradation is a crowded and well-funded modality with competitors including Arvinas and Kymera Therapeutics also advancing clinical-stage degrader pipelines, so C4's platform technology, while sophisticated, does not yet confer an efficient-scale barrier. |